protein

Apolipoprotein A1 - Ultra Pure, Human Plasma

MBS173254

0.1 mg

150 USD

Protein

Apolipoprotein A1 - Ultra Pure, Human Plasma

Apolipoprotein A1

APO A1; Apolipoprotein A1 (APO A1), Human - Low Endotoxin

apolipoprotein A1, partial; Apolipoprotein A-I; apolipoprotein A-I; apo-AI; apolipoprotein A-I; Apolipoprotein A1Cleaved into the following 2 chains:Proapolipoprotein A-I; ProapoA-I; Truncated apolipoprotein A-IAlternative name(s):Apolipoprotein A-I(1-242)

ApoA1

APOA1; APOA1; Apo-AI; ApoA-I; ProapoA-I

APOA1_HUMAN

67

> 96% (SDS-PAGE)

10mM ammonium bicaronate pH7.4 filtered through a 0.22 micron hydrophilic filter. Appearance: Frozen Liquid

At -20 degree C

Source: Human Plasma. pH: 7.4. Protein: 2.0mg/ml (BCA). Recovery: Microfuge vial before drawing from container.

Recertification: 2 years. Handling Information: Handle as a potentially hazardous substance. Refer to MSDS. Product is soluble in aqueous buffers at low concentrations, < 50ug/ml, but due to amphipathic nature it will self-associtate into oligomers at high concentrations in the absence of chaotropes (urea, guanidine hydrochloride). Microfuge vial before drawing from container.

Proteins; Antigens; Standards/controls; Native Proteins; Apolipoprotein A1 (apo A1)

Custom preparations, technical support, bulk quantities and aliquoting available. Apo-AI comprises ~70% of the protein moiety in HDL. It is a single polypeptide chain consisting of 245 amino acids with glutamic acid as the C-terminal residue and aspartic acid as the N-terminal residue. The molecular mass is reported to be 28.3 kDa. The protein is made up of one major isoform (pI 5.6) and two minor isoforms (pI 5.53 and 5.46). Apo-AI shows a high content of a-helix structure. The amphipathic regions in the helix structure seem to be responsible for lipid binding capacity. In aqueous solution, Apo-AI shows self-association with minor conformation change. Apo-AI activates lecithin-cholesterol (LCAT) acyltransferase, which is responsible for cholesterol esterification in plasma. Apo-AI levels in normal plasma are 90-130 mg/dL. Apo-AI levels may be inversely related to the risk of coronary disease.

4960066

AAD34604.1

30,778 Da

ABC-family Proteins Mediated Transport Pathway (106573); ABCA Transporters In Lipid Homeostasis Pathway (477112); African Trypanosomiasis Pathway (194384); African Trypanosomiasis Pathway (194323); Amyloids Pathway (366238); Binding And Uptake Of Ligands By Scavenger Receptors Pathway (771599); Chylomicron-mediated Lipid Transport Pathway (106157); Disease Pathway (530764); Diseases Associated With Visual Transduction Pathway (771581); FOXA2 And FOXA3 Transcription Factor Networks Pathway (137911)

This gene encodes apolipoprotein A-I, which is the major protein component of high density lipoprotein (HDL) in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on chromosome 11. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. [provided by RefSeq, Jul 2008]

APOA1: Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility. Interacts with APOA1BP and CLU. Component of a sperm activating protein complex (SPAP), consisting of APOA1, an immunoglobulin heavy chain, an immunoglobulin light chain and albumin. Interacts with NDRG1. Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b genotype and exposure to cigarette smoking. It is also present in increased levels in aortic lesions relative to native ApoA-I and increased levels are seen with increasing severity of disease. Belongs to the apolipoprotein A1/A4/E family. Protein type: Secreted, signal peptide; Lipid-binding; Endoplasmic reticulum; Cell development/differentiation; Secreted; Vesicle; Motility/polarity/chemotaxis. Chromosomal Location of Human Ortholog: 11q23-q24. Cellular Component: extracellular space; chylomicron; cell surface; endoplasmic reticulum lumen; endocytic vesicle; early endosome; plasma membrane; extracellular region; cytoplasmic vesicle; nucleus; cytosol; vesicle. Molecular Function: identical protein binding; lipase inhibitor activity; beta-amyloid binding; cholesterol binding; phosphatidylcholine binding; high-density lipoprotein binding; protein binding; enzyme binding; phospholipid transporter activity; cholesterol transporter activity; chemorepellent activity; phospholipid binding; apolipoprotein A-I receptor binding; apolipoprotein receptor binding. Biological Process: phototransduction, visible light; negative chemotaxis; negative regulation of lipase activity; axon regeneration in the peripheral nervous system; sequestering of lipid; negative regulation of interleukin-1 beta secretion; regulation of cholesterol absorption; transforming growth factor beta receptor signaling pathway; positive regulation of stress fiber formation; response to drug; platelet activation; cholesterol metabolic process; organ regeneration; regulation of Cdc42 protein signal transduction; adrenal gland development; positive regulation of hydrolase activity; positive regulation of Rho protein signal transduction; lipoprotein metabolic process; positive regulation of transferase activity; vitamin transport; cholesterol biosynthetic process; negative regulation of cytokine secretion during immune response; cholesterol homeostasis; lipoprotein biosynthetic process; response to estrogen stimulus; peptidyl-methionine modification; phosphatidylcholine biosynthetic process; positive regulation of lipoprotein lipase activity; blood vessel endothelial cell migration; cellular lipid metabolic process; platelet degranulation; phospholipid efflux; retinoid metabolic process; transmembrane transport; response to nutrient; phospholipid homeostasis; integrin-mediated signaling pathway; receptor-mediated endocytosis; positive regulation of fatty acid biosynthetic process; regulation of protein amino acid phosphorylation; cholesterol transport; protein stabilization; protein amino acid oxidation; negative regulation of heterotypic cell-cell adhesion; neurite regeneration; cholesterol efflux; G-protein coupled receptor protein signaling pathway; glucocorticoid metabolic process; reverse cholesterol transport; endothelial cell proliferation; negative regulation of inflammatory response; blood coagulation. Disease: Hypoalphalipoproteinemia, Primary; Amyloidosis, Familial Visceral

0.1 mg

150 USD

1 mg

360

3 mg

800